Orange County Ophthalmology Technology Summit
Orange County is the single most technology rich epicenter for ophthalmology technology. The purpose of the Orange County Ophthalmology Technology Summit (Ocots) meeting is to create a local forum where leading ophthalmology technologists, researchers, clinicians, and entrepreneurs can come together to discuss current industry trends, unmet clinical needs, and new business opportunities all to fuel the ophthalmology ecosystem in Orange County, California.
The meeting is sponsored by OCTANe and co-chaired… Show more by Dr. Bill Link, Managing Director of Versant Ventures; founder, chairman, and CEO of Chiron Corporation; and the founder and CEO of American Medical Optics (Amo). Our other co-chair is James V. Mazzo, Executive Chair of Acufocus, retired President of Amo. Jim is truly one of the most distinguished ophthalmology executives in Orange County. After 22 years at Allergan, Jim led the spin out of Amo from Allergan and successfully grew the company to more than $1.5 Billion and clear leadership in cataract, eye care, and refractive surgery. Jim is also co-founder of OCTANe, chairman of the Uci Foundation, and a trustee of Chapman University.
The plethora of ophthalmologic technologies that have been born and developed in Orange County by these co-chairs, along with the large group of executives that they have mentored in their respective organizations, is staggering and has shaped the vision world as we know it today.
At the same time, this field remains in a period of explosive technological growth. Huge unmet clinical needs remain and the rate of innovation continues to accelerate. From an entrepreneurial perspective, change brings opportunity.
Gavin Herbert Recognized and Interviewed at Orange County Ophthalmology Technology Summit Thoughts on Allergan and Ophthalmology in Orange County
Our keynote luncheon presentation at this year’s Orange County Ophthalmology Technology Summit will be a one on one interview with Gavin Herbert by Orange County ophthalmic luminary and Allergan alumnus, Jim Mazzo. This will be a rare opportunity to hear first hand how Orange County has become the global epicenter for the development of innovative ophthalmology technologies, with unscripted commentary about Gavin Herbert’s experiences with Allergan.
Looking to Develop an Innovative Vision Technology? Bill Link Outlines the Four Pillars of Innovation This year’s summit is focused on the “Four Pillars of Innovation”: Research Capitalization Regulation Commercialization
All of the content will be divided into practical blocks of information highlighting the key aspects of each pillar and essential strategies for success. We will hear from innovative companies engaged in each specific pillar, and have panel discussions moderated by Orange County’s ophthalmic leaders outlining what it takes to achieve prominence and tactical recommendations for how to get there.
Matthew Jenusaitis - President & CEO, OCTANe
Matthew Jenusaitis joined as the president and CEO of OCTANe in June 2009. Prior to OCTANe, Matthew spent 15 years at Boston Scientific, where he served in numerous executive marketing and general management positions. Matthew was also an executive in residence for the private equity firm Warburg Pincus and President of ev3 Neurovascular, one of Warburg’s portfolio companies.
Matthew sits on the boards of Creagh Medical in Galway, Ireland; Precision Wire Components in Portland, Oregon; and Pulsar Vascular in San Jose, California. He also sits on the advisory boards of Cornell’s School of Biomedical Engineering, the Chapman University Schmid College of Science and Technology, and the Keck Graduate Institute of Applied Life Sciences. Matthew holds a B.S. in Chemical Engineering, cum laude, from Cornell University, a M.S. in Biomedical Engineering from Arizona State University, and a MBA from UC Irvine.
James Mazzo - Executive Chair, Acufocus
James (Jim) Mazzo is the Operating Partner for Versant Ventures, Executive Chair and Chief Executive Officer (CEO) of AcuFocus, and Executive Chair of Neurotech. As Versant’s first Operating Partner, Mr. Mazzo’s focus is on patient needs, new technology advancements and investment opportunities in the healthcare field worldwide. Versant Ventures is a leading venture capital firm that invests in innovative, groundbreaking bio-pharmaceuticals, medical devices, and other life science opportunities. Founded in 1999, the firm consists of an experienced team committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. He is also an advisor and board member to additional Versant portfolio companies.
Roger Steinert, MD - Chair of Ophthalmology & Director, Gavin Herbert Eye Institute, UCI
Dr. Steinert’s advanced skill and excellent surgical results have earned him a reputation as an international consultant and leader in cataract surgery, refractive surgery and corneal transplants. He has conducted numerous, high-profile research studies and remains at the forefront of innovation developments in refractive surgery. He is recognized in the recent edition of America’s Top Doctors as one of only four physicians to be named in three categories of special expertise.
Gavin Herbert - Founder, Gavin Herbert Eye Institute
UC Irvine’s Gavin Herbert Eye Institute is Orange County ’s premier eye-care provider, offering state-of-the-art ophthalmic services, ranging from routine ophthalmic evaluations to complex medical management and surgical care. Our faculty of internationally recognized physicians, surgeons and scientists provide highly specialized training to future ophthalmologists, access to leading-edge clinical trials as well as sight-saving treatments and therapies for virtually any eye disorder.
Louis Bunn - CFO, ReVision Optics
Louis Bunn has over 15 years experience as a senior financial executive with development-stage medical device companies. He was instrumental in raising over $100 million in venture equity and debt, as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value.
Most recently, Mr. Bunn was Chief Financial Officer and Senior Vice President of Finance & Administration of 3F Therapeutics, Inc., a company that focused on tissue heart-valve products. 3F Therapeutics, Inc. was acquired by Ats Medical, Inc. in September 2006. Previously, Mr. Bunn was Chief Financial Officer and General Manager of EndiCOR Medical, Inc., a company specializing in coronary catheter products. The company was acquired by Ev3, Inc. in 2002. Prior to EndiCOR, Mr. Bunn served as Vice President and Chief Financial Officer of SenDx Medical, Inc., a critical care diagnostic equipment company, which was acquired by Radiometer in 1998. Mr. Bunn is a certified public accountant (inactive) and has a Ba in Business Administration from San Diego State University.
Ellen Darling - Partner, K&L Gates
Ellen Darling's practice is concentrated in product liability and commercial litigation. She represents manufacturers in product liability litigation involving pharmaceuticals, medical devices, motor vehicles, motorcycles, and machinery. In addition, Ellen represents health care providers and lab companies in medical malpractice cases, and counsels companies regarding Consumer Product Safety Commission reporting requirements.
Tom Frinzi - President & CEO, WaveTec Vision
Mr. Thomas G. Frinzi, Tom served as the Chief Executive Officer and President at WaveTec Vision Systems, Inc. Mr. Frinzi served as Chief Executive Officer at Refractec, Inc. since June 2006 and served as its President. Previously, Mr. Frinzi served as Chief Operating Officer at Refractec, Inc. since November 2005. Most recently, he served as Vice President of Global Commercial Operations at Bausch and Lomb Surgical. Since joining Refractec in 2000, he has led the development of global sales and marketing teams to commercialize Refractec's latest technology, NearVision Conductive Keratoplasty (CK). he, who began his career at Johnson & Johnson, is a 30 year veteran of the ophthalmic and medical device industries. He held various executive roles at Refractec, including President and CEO and Chief Operating Officer after an earlier role with Bausch and Lomb, where as Vice President of Sales, he managed numerous product launches with a sharp focus on the growth and expansion of the ophthalmic market. His ophthalmic career also includes long tenures at Chiron Vision Corp. and Iolab Corp. He received a BS degree in Political Science from the University of Tampa.
Nahum Ferera - CEO, Eye-Yon
Nahum Ferera, CEO, is an entrepreneur who specializes in leading medical device projects from an idea to a successful product. Nahum Ferera holds a BSc in Bio-medical Engineering and an MBA, both from Tel Aviv University.
Judy Gordon - DVM, Chiron and Clin Reg Consulting
Judy F. Gordon, DVM, founder and president of ClinReg Consulting Services, has over 20 years progressive clinical, regulatory, quality and R&D experience in the pharmaceutical and medical device industry. She has worked to gain FDA approval for multiple PMAs for Class III devices, and has made many presentations to Advisory Committees. She has also directed clinical trials of biologics, pharmaceuticals, and Class I, II and III medical devices, from protocol development through clinical reporting to FDA. Furthermore, Dr. Gordon has served as the industry representative to Medical Devices Dispute Resolution Advisory Panel to FDA and the Ophthalmic Devices Advisory Panel to FDA.
Jeff Hoffman - Managing Director, Head of West Coast Healthcare Investment Banking, J.P. Morgan
Jeff Hoffman is a Managing Director and Head of West Coast Healthcare Investment Banking. He has more than 19 years experience in the full range of investment banking activities including financial advisory services, mergers and acquisitions, equity and debt financings, and venture capital investments. Prior to joining J.P. Morgan, Mr. Hoffman was Head of Healthcare Investment Banking at Piper Jaffray, with execution focus on life sciences and medical technology clients. Mr. Hoffman received a BS in Psychology and an MBA from the University of North Carolina at Chapel Hill.
Seph Jensen - President & Coo, TearLab
Mr. Jensen has an accomplished history of sales and marketing, operations and general management success in the ophthalmic industry. He joins TearLab from his current position as Head of Surgical Marketing at Alcon Laboratories Inc. ("Alcon"), having responsibility for more than $1.4 billion in revenue across its cataract, retina and refractive businesses. His 17 years of progressive experience at Alcon includes previous roles managing its full surgical equipment portfolio in the United States, leading its surgical retina equipment portfolio globally, managing its pharmaceutical products marketing in Japan and various other commercial assignments. Mr. Jensen's experience at Alcon brings an important depth of knowledge of the global ophthalmic pharma and device space to TearLab's management team.
Paul McLean - CEO, ClarVista
Bio coming soon....
Monty Montoya - President & CEO, SightLife
Monty Montoya pursues the world-wide elimination of corneal blindness with a passion. For those in the global arena of corneal transplantation and eye banking, he is considered a true social humanitarian for working tirelessly to achieve that major goal for the past 20 years. As the president and CEO of SightLife, Monty leads the only non-profit global health organization solely focused on eliminating corneal blindness in the U.S. and around the world. With his guidance, SightLife's growth has burgeoned from a modest $1.9 million to more than $15 million in eight years, with nearly $10.5 million reinvested back into sight-related programs for low-income populations domestically and abroad.
Ramgopal Rao - Chief Executive Officer, LensGen, Inc.
Mr. Rao is the inventor, founder and CEO of LensGen, Inc., a start-up medical device company that is developing a novel accommodative intraocular lens for presbyopia. He is also leading 2C Tech Corporation, a nanotechnology based device for the treatment of Amd and RP. Mr. Rao co-developed an innovative corneal implant device for presbyopia and cofounded Acufocus, Inc. Prior to that Mr. Rao founded Tomey Technology Inc.,that pioneered the corneal topography imaging technology that is now a standard of care in ophthalmology. Mr. Rao was President of Ophthalmic Group at Premier Laser Systems, Inc.; a publicly held company. He also held various executive positions at Biorad Laboratories, Inc.
Ehsan Sadri, M.D. - FACS
Ehsan Sadri, M.D., Facs, Faao is board-certified, fellowship-trained in cataract surgery, Lasik and glaucoma surgery . He is trained in the most progressive ocular surgical techniques including cataract surgery, phakic intraocular lenses, Lasik, PRK, refractive lensectomy, and Ak. Dr. Ehsan Sadri has performed thousands of eye surgeries utilizing advanced techniques for treatment of myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. Dr. Sadri also has extensive experience and a refined technique in performing many cosmetic procedures such as upper and lower eyelid blepharoplasty.
Murthy Simhambhatla, PhD - Senior Vice President, Abbott Medical Optics
Murthy Simhambhatla, Ph.D., is Senior Vice President, Abbott Medical Optics, heading up the company’s global vision care business. Dr. Simhambhatla was appointed to this position in January 2013. Previously, he served as General Manager of the Ibis Biosciences unit of Abbott Diagnostics. Dr. Simhambhatla joined Abbott in 2006 through its acquisition of Guidant Corporation, as Divisional Vice President and General Manager for Drug Eluting Stents. He also served as General Manager for commercial operations in Australia and New Zealand for Abbott Vascular. Before joining Guidant, Dr. Simhambhatla worked in research and development at Raychem Corporation in Menlo Park, CA.
Anthony Sine - Partner, Strathspey Crown LLC
Mr. Sine, a Partner at Strathspey Crown, leads our mergers, acquisitions, licensing and partnerships practice. From 2010 to 2012, Mr. Sine headed business development for Bausch + Lomb’s surgical division completing more than seven deals in two years on three continents worth more than $600 million (including milestones). Working closely with B+L’s private equity owner, Warburg Pincus, these deals reinvigorated B+L’s worldwide product offering, pipeline and international partners.
Tamar Thompson - Vice President, ADVI
Tamar Thompson is a Vice President at Advi and leads agency engagement across firm specializations. She has more than 15 years of leadership experience in health care, including the ability to develop strategic and tactical recommendations to ensure optimal reimbursement and market access for products. Ms. Thompson holds a M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress California.
She also has active certifications from the American Health Information Management Association (Ahima) as a Certified Coding Specialist (CCS) and Certified Coding Specialist – Physician Based (CCS-P).
Clay Wilemon - CEO, DevicePharm
As founder of DevicePharm, Clay brings over 25 years of experience in healthcare marketing with medical device, pharmaceutical, biotech, and life sciences companies. He has provided strategic marketing counsel to three publicly traded companies during their startup, pre-IPO periods.
Clay is also a founder, director, and patent-holder of Tenex Health and serves on the Advisory Board of DxTerity Diagnostics.
11:00 - 11:30 a.m. Registration & Lunch 11:30 a.m. - 12:30 p.m. Welcome Address - Jim Mazzo 12:30 - 1:00 Keynote - Roger Steinert MD / Monty Montoya 1:00 - 1:30 Pace of Innovation and the Four Pillars of Innovation - Dr. Bill Link 1:30 - 2:15 Company Presentations 2:15 - 2:45 Research Panel Discussion - Moderated by Murthy Simhambhatla, PhD - Amo 2:45 - 3:30 Funding Discussion - Moderated by Jim Mazzo - Executive Chair & CEO, AcuFocus 3:30 - 3:45 Break 3:45 - 4:30 Regulatory Discussion - Moderated by Matthew Jenusaitis - CEO, OCTANe 4:30 - 5:00 Company Presentations 5:00 - 5:30 Commercialization Panel - Moderated by Clay Wilemon - CEO, DevicePharm 5:45 - 6:00 Closing Comments - Mazzo 6:00 - 7:00 Reception
Featured Company Presentations
Cataract surgery is the most frequently performed outpatient surgery in the world driving a lucrative intra-ocular lens market of $3B. Despite many refinements, choosing the right intra-ocular lens is challenging and Iol exchange is difficult and risky. Using traditional techniques, 40%-50% of the time the wrong Iol is implanted leaving the patient with suboptimal vision. ClarVista Medical is anophthalmic device start-up raising series B financing to develop and obtain Ce mark of the Harmonitm Modular Intra-Ocular Lens System, the world’s first fully tailorable Iol. Tailorable Iol technology delivers unparalleled versatility to the surgeon and superior refractive outcomes for the patient.
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The Company operates within the Van Leer Technology Incubator.
Almost everyone who enters their 40′s begins to notice changes in their vision, especially their near vision. This typically signals the onset of Presbyopia, a condition in which the eye exhibits a progressively diminished ability to focus on near objects. As we progress from mid-life into our 60′s it is also likely that in addition to Presbyopia, we may also encounter the visual effects caused by the formation of Cataracts, where the natural crystalline lens begins to cloud or become opaque preventing a clear image from forming on the retina. It is at this visual stage in life that one would consider having cataract surgery. By 2018 it is estimated that over 22 million cataract procedures will be performed worldwide and that number will continue to skyrocket as the baby boomers mature.
The TearLab Osmolarity System is the first objective and quantitative test for diagnosing and managing Dry Eye patients. The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of dry eye disease in patients suspected of having dry eye disease, in conjunction with other methods of clinical evaluation. TearLab is for professional in vitro diagnostic use only.
WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. Our revolutionary Ora System® provides intraoperative refractive information to ophthalmologistsworldwide, allowing them to deliver the best possible vision for their cataract patients.
Created by eventbrite | Claim this event
|Check Site||Buy Now|
650 Town Center Dr.
Costa Mesa, CA 92626
Don't Miss This
$16 Spring/Summer Blue Whale Watching Cruise Special
at California Whale Watching-Newport LandingThu 7/24 10:00a
Hot Tickets More »
ON SALE NOW
Thu 7/24 6:00p
Thu 7/24 7:00p
Fri 7/25 7:00p
Sun 9/21 3:00p
Thu 7/24 10:00a
Sat 8/2 8:00p